HIPEC with Cisplatin During Interval Debulking Improves Survival in Stage III Ovarian Cancer

Indications

Contraindications

Survival Benefit

Quality‑of‑Life Impact

Safety Profile

Technical Protocol

Integration with Systemic Chemotherapy

Clinical Decision Algorithm (NCCN)

Clinical Guidelines for HIPEC in Ovarian Cancer

Agent Selection and Dosing

• The National Comprehensive Cancer Network recommends cisplatin as the standard HIPEC agent, specifically at 100 mg/m², which has demonstrated improved disease-free survival and overall survival in patients with ovarian cancer 4, 5
• Cisplatin remains the guideline-endorsed choice for HIPEC in ovarian cancer, based on survival benefit data, with a dose of 75-100 mg/m² 4, 5

Technical Parameters

• The optimal temperature for HIPEC is between 41-43°C, maintained throughout perfusion, as recommended by the National Comprehensive Cancer Network 4, 6, 7
• The duration of HIPEC depends on the agent and dose, with 90 minutes being standard for cisplatin protocols, according to the National Comprehensive Cancer Network 4, 6, 7

Patient Selection Criteria

• The National Comprehensive Cancer Network recommends HIPEC only after neoadjuvant chemotherapy and interval debulking surgery, not after primary debulking surgery, for patients with stage III-IV epithelial ovarian cancer 5
• Complete cytoreduction is the goal before HIPEC administration, as residual disease is the strongest predictor of overall survival, as stated by the National Comprehensive Cancer Network 5
• Patients should have normal renal function, appropriate performance status, and no pre-existing conditions that could worsen significantly, according to the National Comprehensive Cancer Network 8

Systemic Chemotherapy Integration

• The standard neoadjuvant chemotherapy regimen is carboplatin AUC 5-6 + paclitaxel 175 mg/m², administered systemically before surgery, as recommended by the National Comprehensive Cancer Network 4
• A minimum of 6 total cycles of chemotherapy is required, including at least 3 cycles of adjuvant therapy after interval debulking surgery with HIPEC, according to the National Comprehensive Cancer Network 6, 9

Procedural Considerations

• The median procedure time for combined cytoreductive surgery plus HIPEC is 300-600 minutes, with significant blood loss common, as reported by the National Comprehensive Cancer Network 6, 7, 10
• The median hospital stay is 8-24 days, with major/severe complications occurring in 9-40% of patients within 30 days, according to the National Comprehensive Cancer Network 6, 7, 10, 11

Critical Pitfalls to Avoid

• The National Comprehensive Cancer Network recommends not using HIPEC after primary debulking surgery, as initial randomized trial data showed no benefit in this setting 5
• HIPEC should not be proceeded with if complete cytoreduction cannot be achieved, as suboptimal debulking negates potential HIPEC benefits, as stated by the National Comprehensive Cancer Network 5

Post-HIPEC Care Essentials

Antiemetic Management

• The National Comprehensive Cancer Network recommends adding olanzapine 5-10 mg PO daily as first-line agent for breakthrough nausea/vomiting, with alternative agents including lorazepam, metoclopramide, or prochlorperazine 12

Expected Hospital Course

• The National Comprehensive Cancer Network reports a median hospital stay ranging from 8-24 days, with high-quality trials showing minimal difference compared to cytoreductive surgery alone (median 10 vs 8 days) 13
• Grade 3-4 toxicities occur in approximately 27% of patients, similar to cytoreductive surgery alone, according to the National Comprehensive Cancer Network 13

Timing of Adjuvant Chemotherapy

• The National Comprehensive Cancer Network guidelines recommend that patients complete a minimum of 3 cycles (preferably 6 total cycles including neoadjuvant) of systemic chemotherapy, despite the delayed initiation after HIPEC 13

Critical Pitfalls to Avoid

• The National Comprehensive Cancer Network advises confirming that the patient received HIPEC only after neoadjuvant chemotherapy and interval debulking surgery, not after primary debulking surgery, as the latter shows no survival benefit 13